Value through InnovationJune 29 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10
06.28.2016

FDA Advisory Committee recommends approval of Jardiance® (empagliflozin) for cardiovascular indication in 12-11 vote

06.27.2016

New analysis of INPULSIS™ trials demonstrates efficacy of OFEV® (nintedanib) across a range of IPF patients using broader diagnostic criteria

06.14.2016

Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease

06.12.2016

New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes

06.11.2016

Results of Phase III study of volasertib for the treatment of acute myeloid leukemia presented at European Hematology Association Annual Meeting

06.11.2016

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

06.09.2016

Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel treatments for severe fibrotic diseases

06.08.2016

Boehringer Ingelheim and HealthPrize Partner to Launch New Support Program for People Treating COPD With SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray

06.06.2016

Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis

06.02.2016

Boehringer Ingelheim launches ambitious ELUXA trial program to broadly investigate promising lung cancer compound olmutinib

back 1 2 3 4 5 6 7 8 9 10